StockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)

Equities research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued on Friday. The brokerage set a “hold” rating on the stock.

Other research analysts have also issued research reports about the company. Lake Street Capital started coverage on Ekso Bionics in a research report on Monday, June 24th. They set a “buy” rating and a $2.50 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Ekso Bionics in a research note on Tuesday, July 30th.

Ekso Bionics Stock Performance

NASDAQ:EKSO opened at $1.03 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The stock has a 50-day simple moving average of $1.09 and a two-hundred day simple moving average of $1.17. The firm has a market capitalization of $18.72 million, a PE ratio of -1.06 and a beta of 1.45. Ekso Bionics has a 52-week low of $0.75 and a 52-week high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. The firm had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. During the same period last year, the company earned ($0.31) earnings per share. Analysts forecast that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Investors Weigh In On Ekso Bionics

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC boosted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.